Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mometasone
Drug ID BADD_D01490
Description Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Indications and Usage The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
Marketing Status experimental
ATC Code D07AC13; D07XC03; R01AD09; R03BA07
DrugBank ID DB00764
KEGG ID D08227
MeSH ID D000068656
PubChem ID 441335
TTD Drug ID D03HYX
NDC Product Code 65162-891; 69238-2446
UNII 8HR4QJ6DW8
Synonyms Mometasone Furoate | Furoate, Mometasone | Nasonex | Mometasone Furoate Monohydrate | Furoate Monohydrate, Mometasone | Monohydrate, Mometasone Furoate | Asmanex Twisthaler | Twisthaler, Asmanex | Asmanex | Rinelon | Elocon | Sch 32088 | Sch-32088 | Sch32088 | Mometasone
Chemical Information
Molecular Formula C22H28Cl2O4
CAS Registry Number 105102-22-5
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual impairment06.02.10.0130.000332%Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Hypoacusis04.02.01.0060.000089%
Seasonal allergy10.01.04.001; 06.04.01.013; 22.04.04.0080.000404%Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Rhinalgia22.12.03.0200.000303%Not Available
Large intestine polyp16.05.02.006; 07.20.01.010--Not Available
Ear discomfort04.03.01.0050.000404%Not Available
Eye pruritus06.04.05.0060.000303%Not Available
Respiratory tract congestion22.02.07.0030.000202%Not Available
Nasal discomfort22.12.03.0120.001674%Not Available
Skin bacterial infection23.11.02.017; 11.02.01.007--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.000202%Not Available
Adverse event08.06.01.0100.000736%Not Available
Bacterial infection11.02.01.005--Not Available
Biliary tract disorder09.02.03.0010.000059%Not Available
Mediastinal disorder22.09.03.001--Not Available
Abnormal behaviour19.01.01.0010.000059%Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Nasal disorder22.04.03.0040.000433%Not Available
Sinus disorder22.04.06.0020.000766%
Poor quality sleep19.02.05.005; 17.15.04.0020.000303%Not Available
Increased upper airway secretion22.12.03.0070.000303%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000160%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.0160.000504%
Upper-airway cough syndrome22.12.03.0360.000706%
Foetal growth restriction18.03.01.0020.000059%
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene